Form 4: Rocket Pharmaceuticals Director Roderick Wong Boosts Equity Stake with RSU Grant

Roderick Wong, a Director and 10% owner of Rocket Pharmaceuticals, Inc., was granted 47,667 restricted stock units (RSUs) on June 18, 2025, including units in lieu of director fees, which are set to vest on June 18, 2026.

Summary

• Roderick Wong, a Director and 10% owner of Rocket Pharmaceuticals, Inc. (RCKT), acquired 47,667 shares of Common Stock through Restricted Stock Unit (RSU) grants on June 18, 2025.
• The acquisition includes 30,000 RSUs and an additional 17,667 RSUs issued in lieu of director retainer fees totaling $50,000.
• All 47,667 RSUs will vest in full on June 18, 2026.
• Following these transactions, Roderick Wong directly beneficially owns 47,667 shares of Common Stock.
• Additionally, Roderick Wong indirectly beneficially owns 18,188,457 shares of Common Stock through certain investment funds managed by RTW Investments, LP, where he serves as Managing Partner and Chief Investment Officer.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While a routine insider filing, the acquisition of additional equity by a director and 10% owner, particularly in lieu of cash compensation, generally signals confidence and strengthens alignment with shareholder interests.

Positives

• The grant of Restricted Stock Units (RSUs) to a Director and 10% owner aligns the interests of Roderick Wong with those of Rocket Pharmaceuticals' shareholders, as the value of his compensation is tied to the company's future stock performance.
• The decision to issue RSUs in lieu of cash for director retainer fees demonstrates a commitment to equity-based compensation, further strengthening the insider's vested interest in the company's long-term success.

Future Outlook

The Restricted Stock Units (RSUs) granted to Roderick Wong are scheduled to vest in full on June 18, 2026, indicating a future increase in his direct equity stake in Rocket Pharmaceuticals, Inc. upon vesting.

Management Comments

• Roderick Wong serves as a Director and 10% owner of Rocket Pharmaceuticals, Inc., and is also the Managing Partner and Chief Investment Officer of RTW Investments, LP, which manages investment funds holding a significant indirect stake in the Issuer.
• A portion of the Restricted Stock Units (RSUs) granted were issued in lieu of director retainer fees totaling $50,000.

Industry Context

The grant of equity compensation, such as Restricted Stock Units (RSUs), to directors and significant shareholders is a common practice across various industries, particularly in biotechnology and pharmaceuticals, to align the interests of key individuals with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Equity compensation for directors, including the issuance of Restricted Stock Units (RSUs) in lieu of cash fees, is a widely adopted practice in corporate governance across industries, including the biotechnology sector where Rocket Pharmaceuticals operates.
• The specific number of RSUs granted and the value of director fees converted would typically be benchmarked against compensation practices at comparable biopharmaceutical companies of similar market capitalization and stage of development, though specific comparative data is not provided in this filing.

Corporate Governance

Related Party Transactions

• Roderick Wong's indirect beneficial ownership of 18,188,457 shares is through investment funds managed by RTW Investments, LP, where he serves as Managing Partner and Chief Investment Officer. This represents a significant related-party holding.

Stakeholder Impact

• Shareholders: The increased equity stake of a director and 10% owner through RSU grants can be viewed positively, as it further aligns management's interests with shareholder returns.
• Employees: No direct impact on employees is indicated in this filing.

Next Steps

• The Restricted Stock Units (RSUs) granted to Roderick Wong are scheduled to vest in full on June 18, 2026.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Roderick Wong, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Beneficial Ownership, Director Compensation, Equity Grant